Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping acupoints may ease period pain for autoimmune patients

NCT ID NCT06976151

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether transcutaneous electrical acupoint stimulation (TEAS) — a gentle electrical pulse applied to specific points on the body — could reduce period pain and inflammation in women with autoimmune diseases like rheumatoid arthritis or lupus. Fifty-two women received either standard painkillers alone or painkillers plus TEAS sessions three times a week. Researchers measured pain, walking speed, and blood markers of inflammation over three menstrual cycles.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcutaneous electrical acupoint stimulation (TEAS) plus diclofenac (NSAID)
What this could lead to
If it works, this could offer a drug-free add-on to help manage painful periods in women with autoimmune conditions.
What could go wrong
This is a small, completed trial with only 52 participants, so results may not apply to everyone. The treatment is an add-on to standard painkillers, not a replacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

May 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All women will be diagnosed with Rheumatoid arthritis(RA) or Systemic lupus erythematosus (SLE). * All women will suffer from severe pain during menstruation * Age will range from 25-40 years old. * Body mass index: 18.5- 30 Kg/m² * All women participated in the study will have regular menstrual cycle Exclusion Criteria: * Secondary dysmenorrhea * Any other autoimmune diseases not mention in research * Cardiac or respiratory diseases * Vaginal infection * Anemia diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease rheumatoid arthritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases

Contacts and locations

Locations

  • Lamiaa Mostafa Okeil

    Al Fayyum, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.